Upcoming events – Fibrogen and Alnylam look to broaden their horizons

Welcome to your weekly digest of approaching regulatory and clinical readouts. Fibrogen has numerous balls in the air as it advances its two assets, roxadustat and pamrevlumab. The latter is next due data in Duchenne muscular dystrophy (DMD), with a phase II trial in non-ambulatory patients expected to read out in April.